Literature DB >> 22328315

Guidelines for accurate EC50/IC50 estimation.

J L Sebaugh1.   

Abstract

This article provides minimum requirements for having confidence in the accuracy of EC50/IC50 estimates. Two definitions of EC50/IC50s are considered: relative and absolute. The relative EC50/IC50 is the parameter c in the 4-parameter logistic model and is the concentration corresponding to a response midway between the estimates of the lower and upper plateaus. The absolute EC50/IC50 is the response corresponding to the 50% control (the mean of the 0% and 100% assay controls). The guidelines first describe how to decide whether to use the relative EC50/IC50 or the absolute EC50/IC50. Assays for which there is no stable 100% control must use the relative EC50/IC50. Assays having a stable 100% control but for which there may be more than 5% error in the estimate of the 50% control mean should use the relative EC50/IC50. Assays that can be demonstrated to produce an accurate and stable 100% control and less than 5% error in the estimate of the 50% control mean may gain efficiency as well as accuracy by using the absolute EC50/IC50. Next, the guidelines provide rules for deciding when the EC50/IC50 estimates are reportable. The relative EC50/IC50 should only be used if there are at least two assay concentrations beyond the lower and upper bend points. The absolute EC50/IC50 should only be used if there are at least two assay concentrations whose predicted response is less than 50% and two whose predicted response is greater than 50%. A wide range of typical assay conditions are considered in the development of the guidelines.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22328315     DOI: 10.1002/pst.426

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  174 in total

1.  Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.

Authors:  Hai-bo Yu; Bei-yan Zou; Xiao-liang Wang; Min Li
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

2.  Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Authors:  Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

3.  Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay.

Authors:  Nitzan Ganot; Sigalit Meker; Lilia Reytman; Avia Tzubery; Edit Y Tshuva
Journal:  J Vis Exp       Date:  2013-11-10       Impact factor: 1.355

4.  ADHD modulates the course of delinquency: a 15-year follow-up study of young incarcerated man.

Authors:  Florence Philipp-Wiegmann; Michael Rösler; Oriana Clasen; Toivo Zinnow; Petra Retz-Junginger; Wolfgang Retz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-13       Impact factor: 5.270

5.  Cisplatin-Impaired Adipogenic Differentiation of Adipose Mesenchymal Stem Cells1.

Authors:  Yu-Hsun Chang; Hwan-Wun Liu; Tang-Yuan Chu; Yao-Tseng Wen; Rong-Kung Tsai; Dah-Ching Ding
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

6.  Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Authors:  Malcolm A Smith; John M Maris; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Christopher L Morton; Jianrong Wu; Peter G Smith; Jie Yu; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-10-19       Impact factor: 3.167

7.  Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Authors:  Malcolm A Smith; John M Maris; Richard Lock; E Anders Kolb; Richard Gorlick; Stephen T Keir; Hernan Carol; Christopher L Morton; C Patrick Reynolds; Min H Kang; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

8.  Endothelial barrier protection by local anesthetics: ropivacaine and lidocaine block tumor necrosis factor-α-induced endothelial cell Src activation.

Authors:  Tobias Piegeler; E Gina Votta-Velis; Farnaz R Bakhshi; Mao Mao; Graeme Carnegie; Marcelo G Bonini; David E Schwartz; Alain Borgeat; Beatrice Beck-Schimmer; Richard D Minshall
Journal:  Anesthesiology       Date:  2014-06       Impact factor: 7.892

9.  Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.

Authors:  Carolyn L Fisher; Ross J Resnick; Soumya De; Lucila A Acevedo; Kun Ping Lu; Frank C Schroeder; Linda K Nicholson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

Authors:  David Xu; Donghui Zhou; Khuchtumur Bum-Erdene; Barbara J Bailey; Kamakshi Sishtla; Sheng Liu; Jun Wan; Uma K Aryal; Jonathan A Lee; Clark D Wells; Melissa L Fishel; Timothy W Corson; Karen E Pollok; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2020-05-21       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.